Ontology highlight
ABSTRACT:
SUBMITTER: Lamb YN
PROVIDER: S-EPMC6244606 | biostudies-literature | 2018 Sep
REPOSITORIES: biostudies-literature
Drugs 20180901 14
Elagolix (ORILISSA™), an orally bioavailable, second-generation, non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist, is being developed AbbVie and Neurocrine Biosciences for the treatment of reproductive hormone-dependent disorders in women. In July 2018, the US FDA approved elagolix tablets for the management of moderate to severe pain associated with endometriosis. This approval was based on positive results in two replicate phase III trials; additional phase III trials in t ...[more]